KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Expected to Rise, HC Wainwright Analyst Says

KalVista Pharmaceuticals (NASDAQ:KALV) had its price objective boosted by equities research analysts at HC Wainwright from $27.00 to $37.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s target price suggests a potential upside of 120.24% from the stock’s current price. HC Wainwright also issued estimates for KalVista Pharmaceuticals’ FY2030 earnings at $5.90 EPS.

A number of other research analysts also recently commented on KALV. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, October 8th. Needham & Company LLC raised their target price on shares of KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. JMP Securities upped their price target on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a “market outperform” rating in a report on Friday, September 12th. Wall Street Zen upgraded shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Finally, Citizens Jmp lowered their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research report on Tuesday, November 11th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $29.17.

KalVista Pharmaceuticals Stock Up 6.2%

NASDAQ KALV opened at $16.80 on Friday. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. The company has a market cap of $849.24 million, a price-to-earnings ratio of -4.25 and a beta of -0.14. The company has a 50 day moving average of $14.57 and a 200-day moving average of $13.60. KalVista Pharmaceuticals has a 1-year low of $7.30 and a 1-year high of $19.00.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.04. The company had revenue of $13.69 million for the quarter, compared to analyst estimates of $6.03 million. On average, equities research analysts expect that KalVista Pharmaceuticals will post -3.56 earnings per share for the current fiscal year.

Insider Activity at KalVista Pharmaceuticals

In other news, CFO Brian Piekos sold 4,471 shares of the company’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $13.45, for a total transaction of $60,134.95. Following the completion of the transaction, the chief financial officer directly owned 10,529 shares in the company, valued at approximately $141,615.05. This represents a 29.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Paul K. Audhya sold 5,296 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $71,231.20. Following the completion of the transaction, the insider owned 131,831 shares of the company’s stock, valued at $1,773,126.95. The trade was a 3.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 31,329 shares of company stock valued at $437,371 in the last quarter. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the company. The Manufacturers Life Insurance Company boosted its stake in shares of KalVista Pharmaceuticals by 5.9% during the second quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock valued at $165,000 after purchasing an additional 818 shares in the last quarter. BNP Paribas Financial Markets boosted its position in KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 1,292 shares during the period. Rhumbline Advisers boosted its position in KalVista Pharmaceuticals by 2.8% during the 2nd quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock worth $615,000 after buying an additional 1,458 shares during the period. Police & Firemen s Retirement System of New Jersey grew its holdings in KalVista Pharmaceuticals by 26.8% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,756 shares of the specialty pharmaceutical company’s stock worth $110,000 after acquiring an additional 2,061 shares during the last quarter. Finally, Profund Advisors LLC increased its position in KalVista Pharmaceuticals by 25.9% in the 3rd quarter. Profund Advisors LLC now owns 12,613 shares of the specialty pharmaceutical company’s stock valued at $154,000 after acquiring an additional 2,593 shares during the period.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.